The UK and US have hammered out a important bilateral deal that will guarantee zero import taxes on UK drug shipments going into the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase spending on medicines through the NHS. This pledge guarantees that import taxes on these vital products will remain at zero for a timeframe of the next three years.
This agreement follows recent threats to dramatically increase import taxes on patented pharmaceutical products, with figures floated up to one hundred percent.
"This deal with the UK reinforces the global environment for new treatments and introduces long-overdue equity to U.S.–U.K. medicine commerce," a release noted.
Trade Importance
Pharmaceuticals represent one of the the United Kingdom's most significant export categories to the America, which is clearly the biggest market for leading UK drugmakers.
Export figures indicate that in the year leading up to September, the UK exported drugs totaling £11.1bn to the US. This value accounted for nearly one-fifth of British export trade in that span.
"This guarantee secures employment, stimulates funding and paves the way for the UK to establish itself as a international leader for life sciences," a minister stated.
Key British Pledges
The deal entails several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a target to increase overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount drug companies must return to the NHS to control costs will be restricted at 15%. In the past, refunds exceeded 20%.
Recent Tensions
The pact follows a protracted tension between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
These tensions were heightened by arguments that American customers were charged several times more for the same drugs than patients in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been delayed or abandoned, while substantial expansions have been directed toward projects in the United States.
A senior figure acknowledged that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had decreased as a share of its resources over the previous ten-year period.
